Indications
Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.
Composition
- Active substance
- patiromer sorbitex calcium
- International name (INN)
- patiromer
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Veltassa
- Active substance
- patiromer sorbitex calcium
- ATC code
- V03AE09
- Group
- Various
- Therapeutic area
- Hyperkalemia
- Marketing authorisation holder
- Vifor Fresenius Medical Care Renal Pharma France
- Status
- Authorised